Together we Drive the Future

Biomarker Summit

EARLY BIRD DISCOUNT! Register by Jan 27, 2018 to receive 20% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!

registration button

Biomarker Summit

Inflammatory & Immunological Biomarkers

Neurological Biomarkers

Oncology Biomarkers

Subscribe for updates

Dear Colleague,

The Biomarker Summit 2018, to be held on March 21-23, 2018 in San Diego, CA at the Hilton San Diego Resort & Spa, is a meeting place for leaders in the field to discuss the issues and challenges scientists and researchers face in all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization.

Topics to be covered:

A wide variety of important topics will be covered including biomarker identification, validation, and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, companion diagnostics development, and much more. Through scientific presentations, case studies and panel discussions, these areas will be addressed in an intimate and highly interactive environment with perspectives from industry, academia and the public sector.

Assembling leading scientists, researchers, decision-makers and other players across the industry spectrum, the Summit provides a unique opportunity to gain the latest biomarker developments in four major therapeutic areas, formally organized in the following tracks:

General Session:

  1. Plenary Keynote Session
  2. Big Data Analytics & Bioinformatics for Biomarkers Development
  3. Emerging Technologies in Biomarker Development
  4. Overcoming Challenges of Clinical Validation & Translation
  5. Panel Discussion: Companion Diagnostics Development & Partnering Strategies
  6. Overcoming Commercialization Challenges in Biomarker Development

11th Oncology Biomarkers

  1. Circulating Tumor Cells & Microvesicles
  2. Liquid Biopsy: Circulating DNA & MicroRNA
  3. Immuno-oncology Biomarkers
  4. Novel Technologies in Oncology Biomarkers

7th Neurological Biomarkers

  1. CSF & Blood Based Biomarker Approaches
  2. Monitoring Progression in Neurodegenerative Disorders
  3. Novel Technologies in Neurological Biomarkers

7th Inflammatory & Immunological Biomarkers

  1. Biomarkers of Early Progressive Inflammatory & Immunological Diseases
  2. Biomarkers & Surrogate Endpoints for Clinical Trials in Inflammatory Diseases
  3. Microbiomes in Immune Modulation & Inflammatory Diseases
  4. Inflammatory Biomarkers in Respiratory Diseases


Best regards,

The 2018 Advisory Committee

Kian Kani, University of Southern California
Samuil Umansky, DiamiR
Bruce McManus, PROOF Centre of Excellence
Dobrin Nedelkov, Arizona State University
Yong Zhou, Institute for Systems Biology
Kendall Jensen, Translational Genomics Research Institute
Xuemei Zhao, Merck
Chan Whiting, Aduro Biotech
Mark Frasier, Michael J. Fox Foundation
Stephen Johnston, Biodesign Institute, Arizona State University
Roland Staal, Lundbeck Research USA
Parag Mallick, Stanford University
Carrie Brodmerkel, Janssen R&D
Daniel Chelsky, Caprion Proteomics U
Laszlo Takacs, BioSystems International; University of Maryland
Sandip Patel, University of California San Diego
Chinnappa Kodira, GE Global Research Center
Charles Glaus , Amgen
Stephen Pennington, University College Dublin
Jamie (David) Haddon, Genetech
Anuraag Shrivastav, University of Winnipeg
Zhengyan Kan, Pfizer
Andrew Jay, Siemens
John Mayfield, Foundation Medicine
Pierluigi Mauri, CNR, Institute for Biomedical Tecnologies (ITB-CNR)
Nawin Mishra, University of South Carolina
Anuradha Guggilam, Publicis Healthcare Communications group Ltd.